The treatment of various diseases is often hampered by limited efficacy and serious toxicity symptoms as a result of an unfavourable distribution of the drug over the patient’s body. Cristal Therapeutics combines drug molecules with its proprietary CriPec® technology platform, consisting of highly tuneable polymers, biodegradable drug linkers, and if necessary targeting ligands. CriPec enables the rational design and development of targeted nanomedicines. CriPec-based products represent nanomedicines that superiorly treat various diseases including cancer and inflammation.
The strategy of Cristal Therapeutics is to develop a new class of nanomedicines. Applying the CriPec platform results in nanomedicines with a superior product profile as compared to the native drug molecule due to:
- An improved disposition resulting in higher concentrations at the target site
- A prolonged circulation
- A controlled release of the drug at the target site
- Delivery of 100-1000’s active molecules per nanoparticle to the target
These properties translate into a higher efficacy, lower off-target toxicity and an improved safety profile. CriPec-based products represent nanomedicines that superiorly treat various diseases.
CriPec nanomedicines can be targeted to the tissue of interest in a passive way (through the so-called EPR effect) or actively. In case of CriPec actively targeted nanomedicines (CriPec ATN), CriPec nanomedicines are combined with targeting ligands on their surface. With CriPec ATN, the nanomedicines are directed to cellular and even intracellular molecular targets, with additional beneficial features:
- Further increased efficacy and lower off-target toxicity
- More selective tissue and cellular interaction
- Enhanced internalisation, resulting in higher drug levels at the intracellular site of action
CriPec-based products represent nanomedicines that superiorly treat various diseases and an improved safety profile. CriPec-based products represent nanomedicines that superiorly treat various diseases.